US biotech firm ramps up collaboration with Genmab after dropping drug candidate

Bolt Biotherapeutics, a California-based company, is scaling down efforts with one of its cancer candidates to instead increase work on the technology platform that caught Genmab’s eye when it partnered with the firm.

Photo: Shepherd Zhou/AP/Ritzau Scanpix

Genmab has felt the economic consequences of California-based Bolt Biotherapeutics having progressed less than desirably in past years.

In connection with a partnership deal, the Danish biotech firm entered the ownership circle of Bolt in 2021 with a share investment of USD 15m – an investment now worth less than USD 2m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs